ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2332

Suppression of PP2Ac Causes DNA Hypermethylation Through Enhanced Pmek/Perk Activity in T Cells

Katsue S. Watanabe1, Kamalpreet Nagpal2 and George C. Tsokos3, 1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Epigenetics, kinase, methylation and systemic lupus erythematosus (SLE), T cells

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Although many reports have focused on the impaired MEK-ERK signaling pathway in T cells from systemic lupus erythematosus (SLE) patients which results in suppression of DNA methyltransferase (DNMTs) expression and induction of gene transcription of methylation-sensitive genes, the involved mechanisms are still unclear. Here we investigated whether the catalytic subunit of protein phosphatase 2A (PP2Ac) which is overexpressed in SLE T cells contributes to inhibition of MEK-ERK signaling and DNA methylation.

Methods:

Human peripheral CD3 positive T cells from normal subjects were treated with the selective chemical inhibitor, okadaic acid (OA) or transfected with siPP2Ac to achieve sufficient suppression of the PP2Ac enzymatic activity. After stimulation with PMA and ionomycin, DNA, RNA and protein were extracted. The ratio of phosphorylated over total MEK and ERK protein were determined by western blotting. The enzyme activity of DNMTs and the level of global DNA methylation status were calculated by ELISA. The transcription level of two methylation sensitive genes, CD70 and CD11a was quantified by real time RT-PCR.  

Results:

Chemical suppression or siRNA silencing of PP2Ac in T cells resulted in sustained phosphorylation of MEK and ERK following stimulation with PMA and ionomycin compared to T cells in which PP2Ac was not manipulated. PP2Ac suppression resulted in increased DNMT enzymatic activity of DNMT, DNA hypermethylation and decreased expression of methylation-sensitive genes.

Conclusion:

Our results demonstrate that PP2A regulates DNA methylation levels by influencing the phosphorylation levels of the MEK/ERK pathway. We propose that enhanced PP2Ac in SLE T cells may dephosphorylate and activate the upstream signaling pathway of DNMT and disturb the tight control of methylation-sensitive genes such as CD70 and CD11a which are involved in SLE pathogenesis. In addition, based on our previous report that PP2Ac itself is regulated though DNA methylation around a cAMP response element (CRE) binding site located in the proximal promoter, and therefore PP2A may represent a potent accelerator of DNA demethylation through an additional positive feedback mechanism.


Disclosure:

K. S. Watanabe,
None;

K. Nagpal,
None;

G. C. Tsokos,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppression-of-pp2ac-causes-dna-hypermethylation-through-enhanced-pmekperk-activity-in-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology